| Literature DB >> 35215253 |
Seulah Lee1,2, Tae Wan Kim1, Yong Hoon Lee1, Dong-Min Kang3, Rhim Ryoo4, Yoon-Joo Ko5, Mi-Jeong Ahn3, Ki Hyun Kim1.
Abstract
As part of ongoing systematic research into the discovery of bioactive secondary metabolites with novel structures from Korean wild mushrooms, we investigated secondary metabolites from a poisonous mushroom, Omphalotus japonicus (Kawam.) Kirchm. & O. K. Mill. belonging to the family Marasmiaceae, which causes nausea and vomiting after consumption. The methanolic extract of O. japonicus fruiting bodies was subjected to the fractionation by solvent partition, and the CH2Cl2 fraction was analyzed for the isolation of bioactive compounds, aided by an untargeted liquid chromatography mass spectrometry (LC-MS)-based analysis. Through chemical analysis, five fatty acid derivatives (1-5), including two new fatty acid derivatives, omphalotols A and B (1 and 2), were isolated from the CH2Cl2 fraction, and the chemical structures of the new compounds were determined using 1D and 2D nuclear magnetic resonance (NMR) spectroscopy and high resolution electrospray ionization mass spectrometry (HR-ESIMS), as well as fragmentation patterns in MS/MS data and chemical reactions followed by the application of Snatzke's method and competing enantioselective acylation (CEA). In the anti-Helicobacter pylori activity test, compound 1 showed moderate antibacterial activity against H. pylori strain 51 with 27.4% inhibition, comparable to that of quercetin as a positive control. Specifically, compound 3 exhibited the most significant antibacterial activity against H. pylori strain 51, with MIC50 and MIC90 values of 9 and 20 μM, respectively, which is stronger inhibitory activity than that of another positive control, metronidazole (MIC50 = 17 μM and MIC90 = 46 μM). These findings suggested the experimental evidence that the compound 3, an α,β-unsaturated ketone derivative, could be used as a moiety in the development of novel antibiotics against H. pylori.Entities:
Keywords: LC–MS/MS; Marasmiaceae; Omphalotus japonicus; anti-H. pylori activity; fatty acid derivatives
Year: 2022 PMID: 35215253 PMCID: PMC8874359 DOI: 10.3390/ph15020139
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1Separation scheme (top) and chemical structures (bottom) of compounds 1–5.
1H and 13C NMR data for compounds 1 and 2 (δ ppm) a.
| Position | 1 | 2 | ||
|---|---|---|---|---|
| δC |
| |||
| 1 | 177.0 | 174.3 | ||
| 2 | 2.27 t (7.5) | 33.9 | 2.30 t (7.5) | 34.0 |
| 3 | 1.60 m b | 24.3 | 1.62 m b | 24.4 |
| 4 | 1.35 m b | 28.5 | 1.31 m b | 28.8 |
| 5 | 1.35 m b | 28.5 | 1.31 m b | 31.6 |
| 6 | 1.60 m b | 24.3 | 1.62 m b | 24.4 |
| 7 | 2.62 t (7.5) | 39.5 | 2.57 t (7.5) | 40.7 |
| 8 | 202.2 | 200.5 | ||
| 9 | 6.20 d (15.5) | 128.9 | 6.38 dd (16.0, 1.5) | 130.4 |
| 10 | 7.27 dd (15.5, 11.0) | 142.8 | 6.81 dd (16.0, 5.0) | 142.6 |
| 11 | 6.41 dd (15.0, 11.0) | 127.3 | 4.32 ddd (5.0, 3.5, 1.5) | 74.2 |
| 12 | 6.25 dd (15.0, 6.0) | 147.0 | 3.79 m | 74.0 |
| 13 | 4.17 q (6.0) | 71.1 | 1.43 m | 32.1 |
| 14 | 1.54 m | 36.5 | 1.31 m b | 28.8 |
| 15 | 1.35 m b | 24.8 | 1.31 m b | 25.2 |
| 16 | 1.33 m b | 22.2 | 1.31 m b | 22.5 |
| 17 | 1.33 m b | 31.7 | 1.31 m b | 31.6 |
| 18 | 0.91 t (7.0) | 13.0 | 0.90 t (7.0) | 13.9 |
| 1-OCH3 | 3.67 s | 51.3 | ||
a 700 MHz in CD3OD for 1 and 850 MHz in CDCl3 for 2; coupling constants (in Hz) are in parentheses. Assignments were based on the HSQC, HMBC, and TOCSY/1H-1H COSY spectra. b Overlapped.
Figure 2TOCSY (bold lines) and key HMBC (arrows) correlations of 1.
Figure 3(A) CEA reaction for the determination of absolute configuration of compound 1. (B) Proposed favorable transition state of compound 1 in the reaction. (C) Mnemonic to predict the configuration of secondary alcohols in CEA reaction. * defines the chiral center.
Figure 41H-1H COSY (bold lines) and key HMBC (arrows) correlations of 1.
Figure 5Determination of absolute configurations of C-11 and C-12 in compound 2 according to Snatzke’s method. (A) ECD spectrum of 2 and induced ECD spectrum of in situ formed Mo-complex of 2 recorded in DMSO. (B) Favored conformations of Mo-complex of 2.
Anti-H. pylori activity of compounds 1–5.
| Compound | Concentration (μM) | Inhibition (%) | MIC (μM) | MIC50 (μM) | MIC90 (μM) |
|---|---|---|---|---|---|
|
| 100 | 27.4 ± 4.5 b | |||
|
| 11.1 ± 0.3 c | ||||
|
| 97.5 ± 0.8 a | 3.1 | 9 | 20 | |
|
| 2.5 ± 0.8 d | ||||
|
| 0.2 ± 0.1 d | ||||
| Quercetin * | 100 | 34.4 ± 0.6 b | 50 | ||
| Metronidazole * | 97.0 ± 0.1 a | 6.3 | 17 | 46 |
* Positive controls. Data are presented as mean ± SD of experiments in duplicates. Different upper letters in the same column indicate a significant difference (p < 0.05) among the samples.